Asian Outpatients with Schizophrenia: A Double-Blind Randomized Comparison of Quality of Life and Clinical Outcomes for Patients treated with Olanzapine or Haloperidol(cid:31)
Ronnachai Kongsakon1, Pureza Trinidad-O(cid:31)ate2, Haroon Rashid Chaudhry 3, Syed Baqar Raza4, Cynthia R Leynes5, Inam-ur-Rehman Khan6, Hasanah Che Ismail7, Benjamin Chan8, Joy C Ignacio9, Sonia C Rodriguez5, Amanda J Lowry10, Alan JM Brnabic10, Robert Buenaventura11
Affiliation : (cid:31) The abstract was presented at the 16th European Congress of Neuropsychopharmacology (20-24 September 2003, Prague, Czech Republic) 1 Department of Psychiatry, Ramathibodi Hospital, Bangkok, Thailand 2 Cebu Doctors Hospital, Cebu City, Philippines 3 Psychiatry Department, Fatima Jinnah Medical College & Sir Ganga Ram Hospital, Lahore, Pakistan 4 Imam Clinic & General Hospital, Karachi, Pakistan 5 St Luke’s Medical Center, Quezon City, Philippines 6 Department of Psychiatry, Sind Social Security Institution, KV S.I.T.E. Hospital, Karachi, Pakistan 7 Department of Psychiatry, School of Medical Sciences, Universiti Sains Malaysia, Kelantan, Malaysia 8 Hospital Permai, Johor Bahru, Malaysia 9 Department of Psychiatry, Jose Reyes Memorial Medical Center, Manila, Philippines 10 Clinical Outcomes and Research Institute, Eli Lilly Australia Pty Limited 11 Eli Lilly (Philippines) Inc., Pasig City, Philippines
To examine the quality of life (QoL) and clinical outcomes for Asian schizophrenic outpatients treated with olanzapine or haloperidol. Patients were randomized to 24-weeks’ treatment with either olanzapine (n = 144) or haloperidol (n = 132) in a double-blind, prospective, multi-country study. The QLS and WHO- BREF were assessed for QoL; the PANSS, BPRS and CGI scales for clinical status; the BAS, AIMS and SAS scales for physical dysfunction. Regardless of antipsychotic, QoL improved significantly at 8 weeks and maintained this improvement at 24 weeks. Compared with haloperidol, olanzapine treatment was associated with significantly better QoL in the WHO-BREF physical and social relationship domains, better improve- ments in extrapyramidal symptoms in BAS and SAS scores, as well as lower incidence of adverse events. Patients taking haloperidol were more likely to be co-prescribed anticholinergics. The comparatively supe- rior side-effect profile and tolerability of olanzapine may have contributed to enhance domain-specific QoL for these Asian outpatients.
Keywords : Antipsychotic, Asia, Haloperidol, Olanzapine, Quality of life, Schizophrenia
